https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti 2018 false false false United Kingdom French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation brexpiprazole brexpiprazole drug approval europe schizophrenia adult administration, oral product surveillance, postmarketing drug interactions pregnancy breast feeding antipsychotic agents antipsychotic agents drug evaluation, preclinical thiophenes quinolones thiophenes quinolones
--- Summary Basis of Decision (SBD) for Rexulti Brexpiprazole 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg tablets, oral https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00353 2017 false false false Canada French drug information brexpiprazole brexpiprazole drug approval canada treatment outcome schizophrenia antipsychotic agents adult aged brexpiprazole antipsychotic agents tablets administration, oral thiophenes quinolones thiophenes quinolones